Alpha Cancer Technologies (ACT) to Participate in the Gilmartin Group Private Company Showcase

April 17, 2023
Press Release
Toronto, Canada, April 12, 2023 a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that Richard Potts, Chairman, and Dr. Igor Sherman, President & CEO, will give a corporate presentation at Gilmartin Group’s inaugural virtual Spring Private Company Showcase. The company will present on Tuesday, April 18, 2023, at 3:00 p.m. ET.

To attend the virtual presentation, please register using this link